Showing papers by "Hana Müllerová published in 2012"

Inflammatory and repair serum biomarker pattern: association to clinical outcomes in COPD.

Abstract: Background: The relationship between serum biomarkers and clinical expressions of COPD is limited. We planned to further describe this association using markers of inflammation and injury and repair. Methods: We studied lung function, comorbidities, exercise tolerance, BODE index, and quality of life in 253 COPD patients and recorded mortality over three years. Serum levels of Interleukins 6,8 and16, tumor necrosis factor alpha (TNF α) [inflammatory panel], vascular endothelial growth factor (VEGF), and matrix metalloproteinase 9 (MMP-9) [injury and repair panel] and pulmonary and activation-regulated chemokine (PARC/CCL-18) and monocyte chemotactic protein 1 (MCP-1/CCL2) [chemoattractant panel] were measured. We related the pattern of the biomarker levels to minimal clinically important differences (MCID) using a novel visualization method [ObServed Clinical Association Results (OSCAR) plot]. Results: Levels of the inflammatory markers IL-6, TNF α were higher and those of injury and repair lower (p<0.01) with more advanced disease (GOLD 1 vs. 4). Using the OSCAR plot, we found that patients in the highest quartile of inflammatory and lowest quartile of injury and repair biomarkers level were more clinically compromised and had higher mortality (p<0.05). Conclusions: In COPD, serum biomarkers of inflammation and repair are distinctly associated with important clinical parameters and survival.

Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts

Abstract: Background Fibrinogen is a marker of systemic inflammation and may be important in the pathogenesis and progression of chronic obstructive pulmonary disease (COPD).

Fibrinogen, COPD and Mortality in a Nationally Representative U.S. Cohort

Abstract: Background: Fibrinogen is a marker of systemic inflammation and may represent an important biomarker for the progression of chronic obstructive pulmonary disease (COPD). Methods: We used baseline d...

Use of Proteomic Patterns of Serum Biomarkers in Patients with Chronic Obstructive Pulmonary Disease

Abstract: 36. Kanner RE, Connet JE, Murray DA, Buist S, Lee WW, Tashkin DP, Wise R; Lung Health Study. Gender difference in airway hyperresponsiveness in smokers with mild COPD. Am J Respir Crit Care Med 1994; 150:956–961. 37. de Torres JP, Casanova C, Hernandez C, Abreu J, Aguirre-Jaime A, Celli B. Gender and chronic obstructive pulmonary disease in patients attending a pulmonary clinic. Chest 2005;128:20012–20016. 38. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418–1422. 39. Seemungal TAR, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608–1613. 40. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003;48:1204–1213. 41. Bhowmik A, Seemungal TAR, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114–120. 42. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297–1303. 43. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005–1012.

GOLD assessment of COPD patients: Impact of symptoms assessment choice

Abstract: Background : The 2011 GOLD guidelines recommend combined COPD assessment using symptoms (modified Medical Research Council Dyspnoea [mMRC] ≥2 or COPD Assessment Test [CAT] ≥10) combined with a history of exacerbations in the past 12mo {0,1} vs 2+ and spirometric classification GOLD I/II vs III/IV. Four groups are identified, A : low symptoms+low risk; B : high symptoms+low risk; C : low symptoms+high risk; D : high symptoms+high risk. Objectives : Characterize the 4 groups using the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) cohort. Methods : 2028 COPD patients, FEV1 Results : The 4 groups were comparable on age and gender, but had different characteristics. Size of patient groups classified by mMRC were A: 23%, B: 14%, C: 23%, D: 40%; by SGRQ, A: 9%, B: 28%, C: 3%, D: 60%. Compared to the SGRQ, patients classified as 9low symptoms9 (GOLD A & C) using mMRC had worse health status, more fatigue and lower exercise capacity (6MWD). Categorising mMRC as 0 vs. ≥1 produced groups of similar size to those classified by SGRQ: A: 9%, B: 29%, C: 4%, and D: 59%. The kappa of agreement for group membership defined by SGRQ and mMRC increased from 0.2 (mMRC ≤1 vs ≥2) to 0.5 (mMRC 0 vs ≥1). Conclusions : The new assessment permits classification of COPD patients beyond airflow obstruction. GOLD recommends either CAT ≥10 or mMRC ≥2 as the symptomatic cut-point, but this analysis suggests that mMRC ≥1 will classify patients more closely to using the CAT. Clinicaltrials.gov NCT00292552; GSK study SCO104960.